BRPI0707543B8 - composição de polipeptídeo e uso da mesma - Google Patents

composição de polipeptídeo e uso da mesma

Info

Publication number
BRPI0707543B8
BRPI0707543B8 BRPI0707543A BRPI0707543A BRPI0707543B8 BR PI0707543 B8 BRPI0707543 B8 BR PI0707543B8 BR PI0707543 A BRPI0707543 A BR PI0707543A BR PI0707543 A BRPI0707543 A BR PI0707543A BR PI0707543 B8 BRPI0707543 B8 BR PI0707543B8
Authority
BR
Brazil
Prior art keywords
polypeptide
seq
composition
vaccine
drug composition
Prior art date
Application number
BRPI0707543A
Other languages
English (en)
Inventor
Alan Stoloff Gregory
Romero Caparros-Wanderley Wilson
Original Assignee
Peptcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38109631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0707543(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602416A external-priority patent/GB0602416D0/en
Application filed by Peptcell Ltd filed Critical Peptcell Ltd
Publication of BRPI0707543A2 publication Critical patent/BRPI0707543A2/pt
Publication of BRPI0707543B1 publication Critical patent/BRPI0707543B1/pt
Publication of BRPI0707543B8 publication Critical patent/BRPI0707543B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

polipeptídeo, composição de polipeptídeo, metodos para produzir um polipeptídeo e uma construção de polipeptídeos, composição de vacina ou medicamento contra influenza, metodo para produzir uma composição de vacina ou medicamento, uso de um polipeptídeo, uma composição de polipeptídeo, uma construção de polipeptídeo ou uma composição de vacina ou medicamento, e, método de tratamento ou prevenção de influenza provê-se um polipeptídeo não tendo mais do que 100 aminoácidos, cujo polipeptídeo compreende uma ou mais seqüências tendo pelo menos 60% de homologia com qualquer uma de seq id 1-6 ou compreende dois ou mais epítopos tendo 7 aminoácidos ou mais, cada epítopo tendo, pelo menos, 60% homologia com uma sub-seqüência de qualquer seq id 1-6, que tem o mesmo comprimento que o epítopo: seq id 1 dlealmewlktrpilspltkgilgfvftltvp, seq id 2, llyclmvmylnpgnysmqvklgtlcalcekqashs, seq id 3, dliflarsalilrgsvahksc, seq id 4 pgiadiedltllarsmvwrp, seq id 5 llidgtaslspgmmmgmfnmlstvlgvsilnlgq, seq id 6 iigilhlilwildrlffkcfyrlf em que o polipeptídeo é imunogênico em um vertebrado expressando um alelo do complexo de histocompatibilidade principal (mhc), e em que o polipeptídeo não é uma proteína do vírus de influenza completa.
BRPI0707543A 2006-02-07 2007-02-05 composição de polipeptídeo e uso da mesma BRPI0707543B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0602416A GB0602416D0 (en) 2006-02-07 2006-02-07 Peptide sequences and compositions
GB0602416.0 2006-02-07
GB0613977.8 2006-04-13
GBGB0613977.8A GB0613977D0 (en) 2006-02-07 2006-07-13 Peptide sequences and compositions
PCT/GB2007/000383 WO2007091030A2 (en) 2006-02-07 2007-02-05 Peptide sequences and compositions

Publications (3)

Publication Number Publication Date
BRPI0707543A2 BRPI0707543A2 (pt) 2011-05-03
BRPI0707543B1 BRPI0707543B1 (pt) 2020-11-24
BRPI0707543B8 true BRPI0707543B8 (pt) 2021-05-25

Family

ID=38109631

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0707543A BRPI0707543B8 (pt) 2006-02-07 2007-02-05 composição de polipeptídeo e uso da mesma

Country Status (23)

Country Link
US (10) US8475802B2 (pt)
EP (6) EP3320918A3 (pt)
JP (1) JP5603551B2 (pt)
KR (1) KR20080100441A (pt)
CN (3) CN102807608B (pt)
AP (1) AP2646A (pt)
AT (1) ATE534660T1 (pt)
AU (1) AU2007213562A1 (pt)
BR (1) BRPI0707543B8 (pt)
CA (1) CA2641602A1 (pt)
DK (4) DK3263589T5 (pt)
EA (1) EA017387B1 (pt)
ES (4) ES2790730T3 (pt)
GB (1) GB0613977D0 (pt)
HK (1) HK1249115A1 (pt)
IL (2) IL193232A (pt)
MX (1) MX2008010113A (pt)
NO (1) NO20083416L (pt)
NZ (1) NZ570553A (pt)
PL (4) PL1991563T3 (pt)
PT (1) PT1991563E (pt)
SG (1) SG169392A1 (pt)
WO (1) WO2007091030A2 (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0716992D0 (en) * 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
PL2173376T3 (pl) 2007-08-02 2015-08-31 Biondvax Pharmaceuticals Ltd Multimeryczne wieloepitopowe szczepionki przeciwko grypie
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
EP3058954B1 (en) 2007-08-27 2017-03-01 Longhorn Vaccines and Diagnostics, LLC Immunogenic compositions and methods
DK2195466T3 (da) 2007-10-01 2013-01-14 Longhorn Vaccines & Diagnostics Llc Fremgangsmåde til opbevaring af biologiske prøver
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
EP2072529A1 (en) * 2007-12-21 2009-06-24 basisnote AG MHC rapid assay used for the customization of odours
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
CA2828068C (en) 2011-02-22 2019-03-19 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
WO2013112916A1 (en) 2012-01-26 2013-08-01 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
CN107106668A (zh) * 2014-12-10 2017-08-29 华西亚生医有限公司 用于免疫中的有效抗体生产的新颖蛋白质结构
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
CN106310214A (zh) * 2015-06-30 2017-01-11 中国科学院上海巴斯德研究所 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
KR101888751B1 (ko) * 2016-09-22 2018-09-21 이화여자대학교 산학협력단 인플루엔자 b 백신
JP2020515283A (ja) * 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
US11576962B2 (en) 2017-12-21 2023-02-14 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
US12616745B2 (en) 2019-06-07 2026-05-05 Flugen, Inc. Influenza virus backbone
MX2023000881A (es) * 2020-07-21 2023-02-22 Flugen Inc Estructura genomica del virus de la influenza.

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981782A (en) 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU3727895A (en) 1994-09-30 1996-04-26 St. Jude Children's Research Hospital Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
US7269219B1 (en) * 1997-02-14 2007-09-11 At&T Corp. Non-linear quantizer for video coding
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
AU2002223398A1 (en) 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
ES2327103T3 (es) * 2000-09-25 2009-10-26 Polymun Scientific Immunbiologische Forschung Gmbh Vacuna viva de influenzavirus y procedimiento de fabricacion.
US6906169B2 (en) 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
US20050013826A1 (en) * 2002-12-20 2005-01-20 Shneider Alexander M. Vaccine compositions and methods
US7262045B2 (en) * 2003-02-25 2007-08-28 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
BRPI0407877A (pt) 2003-03-07 2006-03-01 Merck & Co Inc conjugado de peptìdeo-proteìna, vacina para a prevenção ou melhora da infecção pelo vìrus influenza, e, método para induzir um resposta imune em um paciente
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
DE102004052026B4 (de) * 2003-11-07 2015-08-27 Totankako Co., Ltd. Kollektor
FR2863758B1 (fr) * 2003-12-11 2006-07-14 Centre Nat Rech Scient Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
EP2489739B1 (en) * 2005-04-21 2019-11-20 University of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
KR20140029551A (ko) 2006-02-02 2014-03-10 글로브이뮨 면역 반응 유도를 위한 효모-기반 백신
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions

Also Published As

Publication number Publication date
HK1249115A1 (en) 2018-10-26
EP1991563A2 (en) 2008-11-19
US20180147277A1 (en) 2018-05-31
ES2790730T3 (es) 2020-10-29
CN101395176B (zh) 2013-02-06
US8475802B2 (en) 2013-07-02
EP3263589A3 (en) 2018-02-14
US11439702B2 (en) 2022-09-13
US20180185470A1 (en) 2018-07-05
CN102382179A (zh) 2012-03-21
EP2383285A2 (en) 2011-11-02
US9446116B2 (en) 2016-09-20
ATE534660T1 (de) 2011-12-15
EA017387B1 (ru) 2012-12-28
JP2009526028A (ja) 2009-07-16
EP2383284A2 (en) 2011-11-02
MX2008010113A (es) 2009-01-19
IL251867B (en) 2018-06-28
GB0613977D0 (en) 2006-08-23
US9889191B2 (en) 2018-02-13
PT1991563E (pt) 2011-12-29
US10335480B2 (en) 2019-07-02
ES2374841T3 (es) 2012-02-22
WO2007091030A2 (en) 2007-08-16
IL193232A (en) 2017-05-29
NO20083416L (no) 2008-11-07
US10765734B2 (en) 2020-09-08
DK3263589T3 (da) 2020-05-11
WO2007091030A3 (en) 2007-11-08
EP3263589B1 (en) 2020-03-25
ES2611034T3 (es) 2017-05-04
US20120219575A1 (en) 2012-08-30
US10279032B2 (en) 2019-05-07
EP2383284A3 (en) 2012-05-30
NZ570553A (en) 2012-08-31
CN102807608A (zh) 2012-12-05
US20230233660A1 (en) 2023-07-27
PL2383285T3 (pl) 2017-11-30
AP2008004571A0 (en) 2008-08-31
ES2635590T3 (es) 2017-10-04
CA2641602A1 (en) 2007-08-16
EP2383285A3 (en) 2012-05-16
BRPI0707543A2 (pt) 2011-05-03
EP1991563B1 (en) 2011-11-23
PL3263589T3 (pl) 2020-07-13
EP2383285B1 (en) 2017-07-12
DK2383284T3 (en) 2016-12-12
CN102382179B (zh) 2014-01-22
DK2383285T3 (en) 2017-08-28
US20200397889A1 (en) 2020-12-24
EA200870237A1 (ru) 2009-06-30
EP3320918A3 (en) 2018-08-01
CN102807608B (zh) 2015-01-21
US20100047275A1 (en) 2010-02-25
EP3263589A2 (en) 2018-01-03
US20170028053A1 (en) 2017-02-02
US8444995B2 (en) 2013-05-21
DK3263589T5 (da) 2020-05-25
AU2007213562A1 (en) 2007-08-16
PL2383284T3 (pl) 2017-07-31
PL1991563T3 (pl) 2012-02-29
IL251867A0 (en) 2017-06-29
US20130243804A1 (en) 2013-09-19
AU2007213562A2 (en) 2008-11-20
SG169392A1 (en) 2011-03-30
US20190201519A1 (en) 2019-07-04
KR20080100441A (ko) 2008-11-18
IL193232A0 (en) 2009-02-11
CN101395176A (zh) 2009-03-25
DK1991563T3 (da) 2012-01-23
US20190365883A1 (en) 2019-12-05
EP2383284B1 (en) 2016-08-24
JP5603551B2 (ja) 2014-10-08
EP3320918A2 (en) 2018-05-16
EP3620463A1 (en) 2020-03-11
AP2646A (en) 2013-04-17
BRPI0707543B1 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
WO2007091030A3 (en) Peptide sequences and compositions
BRPI0912411B8 (pt) uso de uma muteína de interleucina humana-2 (muteína de hil-2) e composição farmacêutica para o tratamento e/ou profilaxia de uma doença autoimune
BRPI0715396B8 (pt) método de produção de uma composição para vacina
BRPI0412202A (pt) emplastro para imunização tendo um arranjo de microprojeções, e método
BR0311777A (pt) Composição de vesìcula meningocócica multivalente, vacina para o tratamento de doença neisserial, métodos para fabricação de composição de vesìcula meningocócica multivalente e para prevenção ou tratamento de doença neisserial, e, uso de uma quantidade imunologicamente eficaz da vacina
UA99659C2 (uk) Мультивалентна вакцина з нативних везикул зовнішньої мембрани менінгококів, способи її застосування
BR112012024806A2 (pt) membro de fixação arcado e implante intervertebral
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
BR112012018951A8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
BR112012018947B1 (pt) anticorpo anti-caprin-1 monoclonal, composição farmacêutica, combinação farmacêutica e usos de uma composição farmacêutica, de um anticorpo e de uma combinação farmacêutica
BRPI0208183B8 (pt) peptídeo antígeno de câncer modificado por wt1 e vacinas para câncer
BR112014021658A2 (pt) composições de neisseria meningitidis e métodos das mesmas
BR0014386A (pt) Composição
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR112013032251A2 (pt) composição estável da vacina da cepa do vírus chikungunya inativado com uma ou mais mutações; método para induzir uma resposta imune protetora em indivíduos humanos contra infecções causadas pelo vírus chikungunya; uso de isolados do vírus chikungunya; composição combinada da vacina
EA201100072A1 (ru) Новые композиции и способы
BRPI0711608B8 (pt) composição liofilizada, uso de antígeno viral, método de tratamento ou prevenção de vírus associado, método de adaptação de um vírus de uma linhagem celular adequada
BRPI0815578B8 (pt) Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer)
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
BRPI0808599A2 (pt) "ácido nucléico, vacina, composição farmacêutica, uso de um ácido nucléico e método para estimular uma imunoresposta versus um epítopo das células t"
BR112018068342A2 (pt) vacina de vírus zika vivo atenuado
BR0309570A (pt) Fatores camp quiméricos para vacinação contra infecção por streptococcus
BR112017017609A2 (pt) proteína de fusão fc, e, composição farmacêutica.
BRPI0514411B8 (pt) formulação, e, método de produzir uma formulação
BRPI0415781A (pt) método para o tratamento de diabetes em um paciente e kit farmacêutico

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time
B11N Dismissal: publication cancelled [chapter 11.14 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 11.4 NA RPI NO 2594 DE 24/09/2020 POR TER SIDO INDEVIDA.

B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/02/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 19A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2865 DE 02-12-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.